This post-marketing study is designed to compare the safety of tofacitinib versus TNF
inhibitor with respect to major cardiovascular adverse events and malignancies, excluding
non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety
events, including non-melanoma skin cancers, hepatic events, infections, and efficacy
parameters will be collected and evaluated in the study.